Plain-English translation of NCT04380545 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a combination of three medications—, , and interferon alpha 2b—to treat fibrolamellar hepatocellular carcinoma, a type of liver cancer that has spread and cannot be removed by surgery. The three drugs work in different ways: one helps your immune system fight cancer, one is a traditional chemotherapy drug, and one is an immune-boosting protein. Researchers want to understand if using all three together is safe and effective.
Fibrolamellar liver cancer that has spread is very difficult to treat, and patients who cannot have surgery need better options. This trial exists to see whether combining these three medications might help control the cancer better than treatments used today.
You likely qualify if…
You likely don't qualify if…
You will receive treatment in 28-day cycles for up to 2 years. In the first 2 cycles, you will receive through an IV continuously on certain days each month and interferon injections under the skin on specific days. Starting in cycle 3, infusions will be added on day 1 of each cycle. After your treatment ends, you will have a follow-up visit 30 days later, then check-ins every 12 weeks for 6 years to monitor how you are doing.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
United States